Most cited papers from Institut Jean Godinot

Institut Jean Godinot

What are the most cited papers from Institut Jean Godinot?

The most cited paper from Institut Jean Godinot is "Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study" (Thomas Bachelot, Gilles Romieu, Mario Campone et al., 2012), with 748 citations. Next come "Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial" (747) and "Strategies of Radioiodine Ablation in Patients with Low-Risk Thyroid Cancer" (698).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 149 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study Thomas Bachelot, Gilles Romieu, Mario Campone et al. · The Lancet Oncology	Nov 2012	748
2	Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial Gwénaëlle Gravis et al. · The Lancet Oncology	8 Jan 2013	747
3	Strategies of Radioiodine Ablation in Patients with Low-Risk Thyroid Cancer Martin Jean Schlumberger, Bogdan Catargi, Isabelle Borget et al. · New England Journal of Medicine Open access	2 May 2012	698
4	Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy Jean-Claude Horiot, René Le Fur, T. Nguyen et al. · Radiotherapy and Oncology	Dec 1992	684
5	Second primary malignancies in thyroid cancer patients Corrado Rubino, Florent de Vathaire, Massimo Eugenio Dottorini et al. · British Journal of Cancer Open access	28 Oct 2003	655
6	Screening for Vulnerability in Older Cancer Patients: The ONCODAGE Prospective Multicenter Cohort Study Pierre Soubeyran, Carine A. Bellera, Jean Goyard et al. · PLoS ONE Open access	11 Dec 2014	601
7	Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients Elisabeth Modigliani, Régis Cohen, José‐Marie Campos et al. · Clinical Endocrinology	Mar 1998	578
8	Exosomes as Potent Cell-Free Peptide-Based Vaccine. I. Dendritic Cell-Derived Exosomes Transfer Functional MHC Class I/Peptide Complexes to Dendritic Cells Fabrice André, Nathalie Chaput, Noël E.C. Schartz et al. · The Journal of Immunology	Feb 2004	498
9	Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy LM Mir, LF Glass, Gregor Serša et al. · British Journal of Cancer Open access	Jun 1998	444
10	Germline mutations in the thyrotropin receptor gene cause non–autoimmune autosomal dominant hyperthyroidism Laurence Duprez, Jasmine Parma, Jacqueline Van Sande et al. · Nature Genetics	Jul 1994	385
11	Improved survival using specialized multidisciplinary board in sarcoma patients Jean‐Yves Blay et al. · Annals of Oncology Open access	25 Aug 2017	382
12	Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial C. Carrié et al. · The Lancet Oncology	8 May 2016	364
13	Peripheral nerves of the extremities: imaging with US. Bruno D. Fornage · Radiology	Apr 1988	360
14	Surgery in reference centers improves survival of sarcoma patients: a nationwide study Jean‐Yves Blay et al. · Annals of Oncology Open access	5 Apr 2019	345
15	6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial Xavier Pivot, Gilles Romieu, Marc Debled et al. · The Lancet Oncology	11 Jun 2013	343
16	Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell–dependent antitumor effects Christophe Borg et al. · Journal of Clinical Investigation Open access	Aug 2004	295
17	Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort Élisa Gobbini et al. · European Journal of Cancer	13 Apr 2018	287
18	Outcomes and patterns of failure in solitary plasmacytoma: A multicenter Rare Cancer Network study of 258 patients Mahmut Özsahin, Richard W. C. Tsang, Philip M. Poortmans et al. · International Journal of Radiation OncologyBiologyPhysics	18 Oct 2005	281
19	Germline BAP1 Mutations Predispose to Renal Cell Carcinomas Tatiana G. Popova et al. · The American Journal of Human Genetics Open access	16 May 2013	280
20	Exosomes as Potent Cell-Free Peptide-Based Vaccine. II. Exosomes in CpG Adjuvants Efficiently Prime Naive Tc1 Lymphocytes Leading to Tumor Rejection Nathalie Chaput, Noël E.C. Schartz, Fabrice André et al. · The Journal of Immunology	Feb 2004	266
21	Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial C. Carrié et al. · The Lancet Oncology Open access	16 Oct 2019	261
22	Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity Jérémy Bastid, Anne Regairaz, Nathalie Bonnefoy et al. · Cancer Immunology Research	17 Nov 2014	255
23	Low-energy He/Ne laser in the prevention of radiation-induced mucositis R.J. Bensadoun, Jean Claude Franquin, Gaston Ciais et al. · Supportive Care in Cancer	1999	255
24	Irinotecan Plus Oxaliplatin and Leucovorin-Modulated Fluorouracil in Advanced Pancreatic Cancer—A Groupe Tumeurs Digestives of the Fédération Nationale des Centres de Lutte Contre le Cancer Study Thierry Conroy, Bernard Paillot, Éric François et al. · Journal of Clinical Oncology	18 Feb 2005	242
25	Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer Sophie Leboulleux et al. · New England Journal of Medicine Open access	9 Mar 2022	240
26	Is prophylactic para-aortic irradiation worthwhile in the treatment of advanced cervical carcinoma? Results of a controlled clinical trial of the EORTC radiotherapy group C. Haie, M.H. Pejovic, Alain P. Gerbaulet et al. · Radiotherapy and Oncology	Feb 1988	232
27	Long-Term Follow-Up of Patients with Papillary and Follicular Thyroid Cancer: A Prospective Study on 715 Patients Maryse Brassard, Isabelle Borget, Agathe Edet‐Sanson et al. · The Journal of Clinical Endocrinology & Metabolism Open access	9 Mar 2011	232
28	Impact on Overall Survival of Radioactive Iodine in Low-Risk Differentiated Thyroid Cancer Patients Claire Schvartz, Franck Bonnetain, Sandrine Dabakuyo et al. · The Journal of Clinical Endocrinology & Metabolism	17 Feb 2012	232
29	Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort Amélie Darlix et al. · British Journal of Cancer Open access	13 Nov 2019	231
30	Male breast cancer: Results of the treatments and prognostic factors in 397 cases B. Cutuli, M Lacroze, Jean-Marie Dilhuydy et al. · European Journal of Cancer	Nov 1995	226
31	Butyrate affects differentiation, maturation and function of human monocyte-derived dendritic cells and macrophages A.-L. Millard, Paul‐Michel Mertès, D. Ittelet et al. · Clinical & Experimental Immunology Open access	17 Oct 2002	219
32	Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: Early and late alterations of left ventricular function during a prospective study Sophie Tassan‐Mangina, D CODOREAN, Marie Métivier et al. · European Journal of Echocardiography	10 Jun 2005	213
33	Killing tumor-associated bacteria with a liposomal antibiotic generates neoantigens that induce anti-tumor immune responses Menglin Wang et al. · Nature Biotechnology Open access	25 Sep 2023	209
34	Comparison of Seven Serum Thyroglobulin Assays in the Follow-Up of Papillary and Follicular Thyroid Cancer Patients Martin Schlumberger et al. · The Journal of Clinical Endocrinology & Metabolism	11 Apr 2007	208
35	C-C chemokines, pivotal in protection against HIV type 1 infection Daniel Zagury, Abderrahim Lachgar, Vida Chams et al. · Proceedings of the National Academy of Sciences Open access	31 Mar 1998	205
36	Incomplete sulphomucin-secreting intestinal metaplasia for gastric cancer. Preliminary data from a prospective study from three centres. Maria Isabel Filipe, François Potet, Wladimir V. Bogomoletz et al. · Gut Open access	Dec 1985	205
37	Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial Karim S. Fizazi et al. · The Lancet Oncology Open access	16 Nov 2014	204
38	The role of spironolactone in the treatment of patients with refractory hypertension James M. Ouzan, Catherine Perault, A. Michael Lincoff et al. · American Journal of Hypertension Open access	Apr 2002	202
39	The G-quadruplex Ligand Telomestatin Inhibits POT1 Binding to Telomeric Sequences In vitro and Induces GFP-POT1 Dissociation from Telomeres in Human Cells Dennis Gómez, Marie-Françoise O’Donohue, Thomas Wenner et al. · Cancer Research	15 Jul 2006	199
40	Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008–2016 Élise Deluche et al. · European Journal of Cancer	2 Mar 2020	193
41	Radiation dose, chemotherapy and risk of osteosarcoma after solid tumours during childhood Béatrice Le Vu, Florent de Vathaire, Akhtar Shamsaldin et al. · International Journal of Cancer	29 Jul 1998	193
42	Localization of a Susceptibility Gene for Familial Nonmedullary Thyroid Carcinoma to Chromosome 2q21 James D. McKay et al. · The American Journal of Human Genetics Open access	Aug 2001	191
43	Significant contribution of large BRCA1 gene rearrangements in 120 French breast and ovarian cancer families Sophie Gad, Virginie Caux‐Moncoutier, Sabine Pagès-Berhouet et al. · Oncogene	2 Oct 2002	190
44	A group specific anamnestic immune reaction against HIV-1 induced by a candidate vaccine against AIDS Daniel Zagury, Jacky Bernard, Rémi Cheynier et al. · Nature	21 Apr 1988	185
45	Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer Paul Henri Cottu et al. · Annals of Oncology Open access	10 Oct 2018	174
46	Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial Martin Jean Schlumberger, Sophie Leboulleux, Bogdan Catargi et al. · The Lancet Diabetes & Endocrinology	26 May 2018	174
47	Targeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer Type Joseph Fabre, Jérôme Giustiniani, Christian Garbar et al. · International Journal of Molecular Sciences Open access	30 Aug 2016	172
48	Clinical, mammographic, and sonographic determination of preoperative breast cancer size Bruno D. Fornage, Olivier Toubas, Michel Morel · Cancer Open access	15 Aug 1987	167
49	Primary breast lymphoma: Patient profile, outcome and prognostic factors. A multicentre Rare Cancer Network study Wendy Jeanneret‐Sozzi, Alphonse G. Taghian, Ron Epelbaum et al. · BMC Cancer Open access	Apr 2008	163
50	18F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO Géraldine Gebhart, Cristina Gámez, Eileen McCormick Holmes et al. · Journal of Nuclear Medicine Open access	3 Oct 2013	162

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.